Jenny L Schnyder

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 170 citations · Full text

Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Luca M. Zaeck, Ngoc H. Tan, Wim J. R. Rietdijk et al. · Nature Communications · 2024 · 15 citations · Full text

Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy

Hannah M Garcia Garrido, Jenny L Schnyder, Beheshta Haydari et al. · International Journal of Antimicrobial Agents · 2022 · 13 citations · Full text

Intradermal immunization—a dose-sparing strategy to combat global shortages of severe acute respiratory syndrome coronavirus 2 vaccines?

Jenny L Schnyder, Hanna K de Jong, Martin P. Grobusch · Clinical Microbiology and Infection · 2021 · 11 citations · Full text